Palbociclib (PD-0332991) HCl

For research use only. Not for use in humans.

Licensed by Pfizer Catalog No.S1116

155 publications

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 155 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MV\LbY5ie2ViQYPzZZk> MlnrNlQhcA>? NFnKfHRKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= MWmyOFY1OTFyMx?=
COLO205 NUD4W21tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\wO|IhcA>? NEjFSIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>? Mn3lNlQ3PDFzMEO=
U937 NF\aW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTMTGhEPzJiaB?= MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN M{PZT|I1PjRzMUCz
MOLM13 M1vmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rFd|czKGh? M{nhSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> MUWyOFY1OTFyMx?=
MOLM13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv1[|ZmPzJiaB?= NFXZO5hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP NVT6Z4xYOjR4NEGxNFM>
MDA-MB-435 M2LZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKyOEBp NV;3V5dVUUN3ME2wMlE3KM7:TR?= MWGxOVgxOTh|MR?=
K562 NH;4botEgXSxdH;4bYMhSXO|YYm= M1HH[|k3KGh? MX3EUXNQ MofTTWM2OD1{IN88US=> NV3UTmM6OjR2MUe1OlY>
DU145 NIDjZ4ZEgXSxdH;4bYMhSXO|YYm= NW[x[3RHQTZiaB?= NUXBNoVXTE2VTx?= NXOwPVl2UUN3ME23MlUh|ryP M1j5elI1PDF5NU[2
MDA-MB-231 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fJWVEh|ryP MXqyOEBp MoPLSG1UVw>? M4WxcmNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> NYK1fFlDOjR2MUe1OlY>
MCF7 Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6yNUDPxE1? Mnz6NlQhcA>? MV7EUXNQ NFzm[mpE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> NX\zTmY3OjR2MUe1OlY>
MCF7 MWDLbY5ie2ViQYPzZZk> NWTFbW9UPSEQvF2= MWqyOEBp NVvkPHRsTE2VTx?= NXHoVohTUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> NXrLb5ByOjR2MUe1OlY>
MDA-MB-231 MlrPT4lv[XOnIFHzd4F6 MVi1JO69VQ>? Mnm4NlQhcA>? MlnHSG1UVw>? M2TkTGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= Mkn6NlQ1OTd3Nk[=
MDA-MB-231 MkjESpVv[3Srb36gRZN{[Xl? MoDhNU0yOCEQvF2= MorjNlQhcA>? M{fUV2ROW09? NYnrZ4p4\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl NHiwenczPDRzN{W2Oi=>
MCF7 MVfGeY5kfGmxbjDBd5NigQ>? MYSxMVExKM7:TR?= NF;lNFMzPCCq MnviSG1UVw>? M1PDdYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NEDj[mQzPDRzN{W2Oi=>
MDA-MB-231 MWLGeY5kfGmxbjDBd5NigQ>? M3W1XlAvPS1zIN88US=> MnjzOFghcA>? MkLRSG1UVw>? MUXoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> NVvvemhVOjR2MUe1OlY>
MCF7 NGPlWXJHfW6ldHnvckBCe3OjeR?= MlLkNE42NTFizszN NInUTnU1QCCq NGDCbHRFVVOR M{DwU4hieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm M{f2fVI1PDF5NU[2
697 NXLyTlVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrrTWM2OD1zNEiuN|ghdk1? MkiwV2FPT0WU
P12-ICHIKAWA MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi5d2VKSzVyPUm2MlA1KG6P M3zYXnNCVkeHUh?=
NB69 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF4MT64JI5O M4X4eXNCVkeHUh?=
EoL-1 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rFZmlEPTB;MUi3MlI3KG6P MUXTRW5ITVJ?
BHT-101 M2\4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCWWlEPTB;MUm4MlI2KG6P MVzTRW5ITVJ?
SK-NEP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrxRVFKSzVyPUKyNE4xOiCwTR?= NVTHUlFYW0GQR1XS
MHH-NB-11 M1S0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ{MD6xPUBvVQ>? NF\KVFRUSU6JRWK=
AsPC-1 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PqO2lEPTB;MkWyMlU{KG6P MVPTRW5ITVJ?
ES1 NX\DO4FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\PTHdKSzVyPUK1Ok4zPSCwTR?= Mo[4V2FPT0WU
LAMA-84 NF65SJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLzTWM2OD1{NUiuNVkhdk1? MljWV2FPT0WU
MOLT-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv5O2s1UUN3ME2yOVgvPDlibl2= MXzTRW5ITVJ?
ES7 NHTCTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\HPZFKSzVyPUK3N{4xQSCwTR?= NYrtVZRxW0GQR1XS
KY821 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfuTllKSzVyPUOxOE4yKG6P MUfTRW5ITVJ?
RT-112 NHXQOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDWTWM2OD1|MkGuNFUhdk1? M4\yRXNCVkeHUh?=
HL-60 NFHR[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITMV2NKSzVyPUO0NE43PiCwTR?= MmXZV2FPT0WU
MOLT-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\vS3VKSzVyPUO0OU4yOyCwTR?= NHL2NWhUSU6JRWK=
KARPAS-45 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTN5Nj6xOkBvVQ>? MoHVV2FPT0WU
SK-N-AS M3\EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nWU2lEPTB;M{i3Mlg{KG6P M{XES3NCVkeHUh?=
CTB-1 M1nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOxSmJKSzVyPUSwOU4xOiCwTR?= NVzJcIpZW0GQR1XS
NKM-1 NX;WT5U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRzMT64PUBvVQ>? MkDYV2FPT0WU
HTC-C3 M2CxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH6TWM2OD12M{KuPVUhdk1? MnnMV2FPT0WU
BE-13 NULocnFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HrNWlEPTB;NES0MlI4KG6P NYnqXJNRW0GQR1XS
KOSC-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHmTWM2OD12Nk[uPUBvVQ>? NXK3R4VbW0GQR1XS
NB14 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln3TWM2OD12OEOuOVghdk1? MoHYV2FPT0WU
CAL-27 NYG5eFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm1OmIzUUN3ME20PVQvPTlibl2= MWPTRW5ITVJ?
H9 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX5[YRrUUN3ME20PVUvPDNibl2= M3Hac3NCVkeHUh?=
RS4-11 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTRTWM2OD13MESuO|Mhdk1? M2DJVHNCVkeHUh?=
PA-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzDTWM2OD13MEmuPFYhdk1? MkTKV2FPT0WU
MV-4-11 M33tcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTVzMz64OUBvVQ>? MWHTRW5ITVJ?
OS-RC-2 NID0cJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPTbnhKSzVyPUWyNU43OiCwTR?= MVTTRW5ITVJ?
RPMI-8226 NHfaeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWey[ol6UUN3ME21NlYvQDZibl2= NIjlbZFUSU6JRWK=
HGC-27 M1LHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTV4ND65PUBvVQ>? MV;TRW5ITVJ?
CHP-212 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTV7Mz61PUBvVQ>? MV\TRW5ITVJ?
NB10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW3cIVKSzVyPUW5PU4yQCCwTR?= NFvObJFUSU6JRWK=
HH Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfE[YFlUUN3ME21PVkvPDNibl2= NGnqeo5USU6JRWK=
EW-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XX[2lEPTB;NkCzMlUzKG6P MXjTRW5ITVJ?
ES8 NEW5[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjF[YlKSzVyPU[wOU4zOSCwTR?= MYXTRW5ITVJ?
HAL-01 M4Ps[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzRTWM2OD14MEWuOlchdk1? NIeyW41USU6JRWK=
A204 M3Syd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX2RZJKSzVyPU[zN{46OSCwTR?= MXjTRW5ITVJ?
MHH-PREB-1 M1T0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrVTWM2OD14M{[uPVkhdk1? M2fmenNCVkeHUh?=
EM-2 NGD1e4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfvfpViUUN3ME22OVAvPjRibl2= MYrTRW5ITVJ?
BV-173 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjsNGdLUUN3ME22OVIvPDhibl2= Mn\OV2FPT0WU
ONS-76 NWe2R2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvF[ZhFUUN3ME22O|cvQDJibl2= M3uybnNCVkeHUh?=
KM-H2 M3PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLmN5ViUUN3ME22PVUvPTRibl2= M4rDc3NCVkeHUh?=
D-263MG MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPRTWM2OD15MUeuNVIhdk1? MkTmV2FPT0WU
ES3 NUPsRpRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTd{OD65N{BvVQ>? MY\TRW5ITVJ?
VA-ES-BJ Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTd|Mj6yO{BvVQ>? MXHTRW5ITVJ?
NBsusSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LZXmlEPTB;N{SyMlk6KG6P MYDTRW5ITVJ?
NCI-H520 NFXaRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT5TWM2OD15NE[uOVIhdk1? MoToV2FPT0WU
ES5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvnTYRKSzVyPUe1Nk45KG6P MmrtV2FPT0WU
T-24 NF7EO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTpTWM2OD15N{iuO|Ehdk1? NFHUeXlUSU6JRWK=
SW962 M{\kNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuxXHpTUUN3ME24NFgvPjNibl2= NH3STZNUSU6JRWK=
EW-3 M4Djbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jiO2lEPTB;OEC4Mlc3KG6P M3z1XHNCVkeHUh?=
RXF393 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRThzMj63PUBvVQ>? NGjR[o5USU6JRWK=
U251 NYHkRZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\aTWM2OD16MUOuPFghdk1? NH;KW5VUSU6JRWK=
CAMA-1 NFTMOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDH[3lKSzVyPUizN{46PCCwTR?= NGLzfHlUSU6JRWK=
JVM-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLIRXpKSzVyPUi1NU44QCCwTR?= MULTRW5ITVJ?
COLO-800 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TDNWlEPTB;OEm3Mlc5KG6P MmixV2FPT0WU
OVCAR-5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfadIMzUUN3ME25NFAvOSCwTR?= NYH1bItmW0GQR1XS
LB1047-RCC NWDuTGozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T4[WlEPTB;OUK3MlU3KG6P NVXh[W5mW0GQR1XS
SW954 NIHNZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2njfGlEPTB;OUK5MlQyKG6P Mm\YV2FPT0WU
J-RT3-T3-5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPQTWM2OD17M{[uNFYhdk1? M3PSZ3NCVkeHUh?=
Mewo M3r2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:wTWM2OD17M{[uOkBvVQ>? MUnTRW5ITVJ?
NCI-H1770 M4PaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r6UGlEPTB;OUSwMlU2KG6P MkLZV2FPT0WU
HO-1-N-1 NH:zcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17wcWlEPTB;OU[yMlgyKG6P M3HCe3NCVkeHUh?=
HSC-3 M4nCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTZTWM2OD17Nk[uOFghdk1? NYDIdIQ5W0GQR1XS
TYK-nu M3XtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILCe5VKSzVyPUm5PE4zPSCwTR?= MkXRV2FPT0WU
KYSE-150 NWLSZmZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjiclFoUUN3ME2xMlAxODd4IN88US=> M4LsdnNCVkeHUh?=
SN12C NXGyWXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7vTWM2OD1zLkCwPFc2KM7:TR?= NVy4SIN4W0GQR1XS
MOLT-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwMEG0NlEh|ryP NHLJe4pUSU6JRWK=
TE-11 M2O3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjLb2hKSzVyPUGuNFQ5OTJizszN M4W0SnNCVkeHUh?=
DB NVPLbnlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMEeyO|Mh|ryP NFfXdIdUSU6JRWK=
CAL-39 NETJdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\BTWM2OD1zLkC3OVIzKM7:TR?= NWLRcpRQW0GQR1XS
A3-KAW M{XXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLSZ|BKSzVyPUGuNFg1ODhizszN NV72bYZMW0GQR1XS
CHP-134 NU\YcFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnTVXp{UUN3ME2xMlEyQDB5IN88US=> NUjSfVdyW0GQR1XS
TGW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjRVY1KSzVyPUGuNVI{QTVizszN M33FenNCVkeHUh?=
QIMR-WIL NFW0OItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmTWM2OD1zLkGzNVM1KM7:TR?= MnnuV2FPT0WU
NCI-SNU-1 NVnlfmFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7MdJVKSzVyPUGuNVY{PTRizszN MVvTRW5ITVJ?
CGTH-W-1 NVryfYw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnZ[HJKSzVyPUGuNVcyQDZizszN NIjzVYVUSU6JRWK=
MHH-ES-1 NHzE[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmyOXRUUUN3ME2xMlE4QTh4IN88US=> MX3TRW5ITVJ?
LB2241-RCC NV;5UmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzrfYRKUUN3ME2xMlE5PjJizszN NGWyfZFUSU6JRWK=
ML-2 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPNfWpKSzVyPUGuNlA4OzRizszN MXXTRW5ITVJ?
COR-L23 M{jJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i1Z2lEPTB;MT6yNlk{OyEQvF2= MknRV2FPT0WU
BFTC-905 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUficnROUUN3ME2xMlI1OjZ5IN88US=> M3\PVHNCVkeHUh?=
Hs-578-T NHr2UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r4bmlEPTB;MT6yOVgyPyEQvF2= M1zsXHNCVkeHUh?=
KG-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXHc25KSzVyPUGuNlY3QDZizszN NU\rWm9zW0GQR1XS
HEL NVHKNWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j1dGlEPTB;MT6yPVM{QCEQvF2= M3G4[nNCVkeHUh?=
A549 NIPYN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DUWWlEPTB;MT6yPVM6QSEQvF2= NXTxWFAzW0GQR1XS
COLO-741 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\JTGlEPTB;MT6zNlA5QSEQvF2= NHTyRmRUSU6JRWK=
PC-3 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXDRVVKSzVyPUGuN|UzOjFizszN NUHBRVdEW0GQR1XS
HOS NITWTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3PTWM2OD1zLkO1Nlk3KM7:TR?= MWPTRW5ITVJ?
HT-1080 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nW[GlEPTB;MT6zO|UyQSEQvF2= NHHUPZZUSU6JRWK=
TE-8 NYXHPXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq4b4pUUUN3ME2xMlQyPzd2IN88US=> M1jtN3NCVkeHUh?=
BHY NYTtS5B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwNE[5NlMh|ryP MVrTRW5ITVJ?
BB65-RCC NHHPVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwNUC1Nlgh|ryP M{Lyc3NCVkeHUh?=
HN MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwNUSwO|Eh|ryP M4LXU3NCVkeHUh?=
NCI-H441 NEnsWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwNUS5NFch|ryP MmDCV2FPT0WU
RPMI-8866 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnuTWM2OD1zLkW4OVA4KM7:TR?= NUiwbXUyW0GQR1XS
CAL-62 NFi2NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwNkC4OlIh|ryP NHz6RVNUSU6JRWK=
MG-63 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvNeoxKSzVyPUGuOlE5OTNizszN Ml3zV2FPT0WU
SK-LU-1 NUTscppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwNkKxOVIh|ryP NWHjXIxKW0GQR1XS
BCPAP NGr0[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPBUHJDUUN3ME2xMlY3PDV5IN88US=> MYXTRW5ITVJ?
22RV1 M2PsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW3TWM2OD1zLk[3PFQ{KM7:TR?= MYfTRW5ITVJ?
T47D NYHMbYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7L[pJrUUN3ME2xMlY5ODZzIN88US=> NFPGc4dUSU6JRWK=
MSTO-211H NILZenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPHOIhQUUN3ME2xMlY6PjB|IN88US=> Mm\6V2FPT0WU
DEL M1:xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTNTWM2OD1zLkewNlc{KM7:TR?= NVrsd5QxW0GQR1XS
H4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\PTHZPUUN3ME2xMlc{OjF{IN88US=> M{H4fHNCVkeHUh?=
CAL-51 M1\D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXwW5F[UUN3ME2xMlc1QDV3IN88US=> NVj6ZnNrW0GQR1XS
ABC-1 NHLuVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[3b|VKSzVyPUGuO|g2QDJizszN Mlv0V2FPT0WU
MZ2-MEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDDPVRLUUN3ME2xMlc6PTR{IN88US=> NY\jVmxnW0GQR1XS
YKG-1 NIDIe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzKSJJKSzVyPUGuPFExPjFizszN Mkj2V2FPT0WU
KM12 NHn0PXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD1zLkixOlAzKM7:TR?= MmfoV2FPT0WU
L-363 NXXidWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwOEe0NVIh|ryP NFPoW5pUSU6JRWK=
KU812 NIXYRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\STWM2OD1zLki5NlgzKM7:TR?= NWX3TYpKW0GQR1XS
LOXIMVI M4HtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwOUGyNlgh|ryP M1HQWHNCVkeHUh?=
G-401 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwOUK0Nlgh|ryP NYm0d2J1W0GQR1XS
SW780 NGH1NGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLwTWM2OD1zLkm2NlQ3KM7:TR?= M3q3b3NCVkeHUh?=
SW872 NH3pN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HySmlEPTB;MT65PFM{KM7:TR?= NY\OeYZrW0GQR1XS
NB7 M3;UWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3RTWM2OD1zLkm5N|I{KM7:TR?= MWPTRW5ITVJ?
T98G M3POXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhV2lEPTB;Mj6wNFY3PiEQvF2= MoSzV2FPT0WU
SW1710 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH4TWM2OD1{LkC2PVQ2KM7:TR?= MWLTRW5ITVJ?
NCI-H1573 M13nTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fmcWlEPTB;Mj6wO|I6QCEQvF2= MWTTRW5ITVJ?
KE-37 M2rsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XJbWlEPTB;Mj6wPFk2OSEQvF2= NGrkfIFUSU6JRWK=
786-0 NHnQOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXubYVKSzVyPUKuNVU1OzlizszN NEjveVdUSU6JRWK=
SAS MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwMkCzO|Qh|ryP M3S3SHNCVkeHUh?=
CAL-54 NFe0dZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMkC0NVMh|ryP MX3TRW5ITVJ?
SF268 NHewWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\2TWM2OD1{LkKzNVIzKM7:TR?= NWXZSZdFW0GQR1XS
SW620 NHG4SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjKVm1KSzVyPUKuNlYyPjlizszN NGPx[JlUSU6JRWK=
MN-60 NGHaXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn2dWdKSzVyPUKuN|ExPiEQvF2= MVTTRW5ITVJ?
EFO-27 NGfBUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDP[4FVUUN3ME2yMlMzODV6IN88US=> MXXTRW5ITVJ?
NCI-H747 NEX6dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOwfZdKUUN3ME2yMlMzOTl7IN88US=> MlHoV2FPT0WU
HCC2218 M1nGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP6WGlkUUN3ME2yMlM2Ozd2IN88US=> NXiz[|E6W0GQR1XS
MIA-PaCa-2 NIjZXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\VTWM2OD1{LkO2OFM4KM7:TR?= NUL0Oo5OW0GQR1XS
SJSA-1 M4jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M120SGlEPTB;Mj6zO|c6PiEQvF2= NGjZfGhUSU6JRWK=
RKO NFTQSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwM{i0PVYh|ryP M4TJN3NCVkeHUh?=
NB6 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LrTGlEPTB;Mj60NFM4PCEQvF2= NGTLcIxUSU6JRWK=
ES4 M4fZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\nS|h3UUN3ME2yMlQ2PDJ{IN88US=> MUjTRW5ITVJ?
EGI-1 NH3aNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTydI5HUUN3ME2yMlQ3QDh|IN88US=> MWjTRW5ITVJ?
CTV-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;Wd41NUUN3ME2yMlUzPzd|IN88US=> MVnTRW5ITVJ?
NCI-H1355 M1r0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrYOXBHUUN3ME2yMlU2QTVzIN88US=> MVLTRW5ITVJ?
GT3TKB M{DyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJwNUmxPVkh|ryP MWfTRW5ITVJ?
SK-HEP-1 NYDIdmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwNUmyOlYh|ryP M3vSO3NCVkeHUh?=
GAMG Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jqeWlEPTB;Mj61PVM6PCEQvF2= M1HDd3NCVkeHUh?=
SK-MES-1 NETlVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPJTWM2OD1{Lk[xPFA{KM7:TR?= NEHXcmNUSU6JRWK=
RO82-W-1 NV7xb|JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTTTWM2OD1{Lk[yNFU4KM7:TR?= M{\KR3NCVkeHUh?=
ECC10 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzuZppXUUN3ME2yMlcxOjB4IN88US=> NIm2Z|JUSU6JRWK=
MCF7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf2PG82UUN3ME2yMlcyPDZ2IN88US=> NEnwbnZUSU6JRWK=
D-283MED NH\2eWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX6TWM2OD1{LkeyOFMh|ryP NHvKd3pUSU6JRWK=
RPMI-7951 M2\kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvS[Y5KSzVyPUKuO|U3QTRizszN M4rNbnNCVkeHUh?=
Ramos-2G6-4C10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwN{ewPVkh|ryP NFPRcmxUSU6JRWK=
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnGd3JKSzVyPUKuPFE5QDRizszN MXvTRW5ITVJ?
NUGC-3 M4GyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwOEK1NFUh|ryP NVvrSGFCW0GQR1XS
NCI-H292 NXKxcY44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJwOEWwOVMh|ryP MVnTRW5ITVJ?
Becker NUTiendQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpTWM2OD1{Lkm1PFMzKM7:TR?= M3S3NHNCVkeHUh?=
NCI-H1299 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HERmlEPTB;Mz6wOVI3OyEQvF2= M3PUUHNCVkeHUh?=
ETK-1 M2\ESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWftVGx1UUN3ME2zMlA2PDNizszN MVzTRW5ITVJ?
TK10 NIn2VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzuTWM2OD1|LkKwNVY2KM7:TR?= NIXPPVBUSU6JRWK=
VMRC-RCZ NG\WOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwM{[0PFgh|ryP NISxV5BUSU6JRWK=
YH-13 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTNwNESwO|kh|ryP NW\3WZp5W0GQR1XS
DU-145 M1KzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfoTWM2OD1|LkS2NlY6KM7:TR?= NHjYPFNUSU6JRWK=
SW1088 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwNEe0O{DPxE1? NUPtZ2VlW0GQR1XS
HOP-92 M1jZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPBZmFSUUN3ME2zMlUxOzR{IN88US=> NGr4WXFUSU6JRWK=
KP-N-YS M3T5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNwNkKxN|kh|ryP NXnk[FVbW0GQR1XS
NCI-H460 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj4N5l3UUN3ME2zMlY3PzNizszN MliwV2FPT0WU
U-2-OS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHC[pJKSzVyPUOuO|I2OzVizszN Mo\PV2FPT0WU
A101D M3L3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwN{[5N|Yh|ryP MXPTRW5ITVJ?
MDA-MB-231 NITOVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHTe3d{UUN3ME2zMlgyQTVzIN88US=> NVXQ[|NTW0GQR1XS
IST-MES1 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHySm9KSzVyPUOuPFMzKM7:TR?= MoO4V2FPT0WU
COR-L105 NUTwb4JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof4TWM2OD12LkCxPEDPxE1? MlzHV2FPT0WU
NCI-H1437 M1XsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTRwMEKzNFIh|ryP NXf1OnN[W0GQR1XS
CAL-85-1 NULJdm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnsTWM2OD12LkCyOFYyKM7:TR?= NGjsWWNUSU6JRWK=
MZ1-PC NXHMdmwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ETWlEPTB;ND6xPFU2PiEQvF2= NWOybpFPW0GQR1XS
VM-CUB-1 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHezO3dKSzVyPUSuN|EzQDRizszN Mmm3V2FPT0WU
CHL-1 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTpTWM2OD12LkOyNVY6KM7:TR?= NFj5cFJUSU6JRWK=
MDA-MB-361 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwM{OxOVMh|ryP NFWwVphUSU6JRWK=
NCI-H661 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XWXmlEPTB;ND61NFA6OiEQvF2= MlfmV2FPT0WU
EW-11 MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYizc2tvUUN3ME20MlUzOjNzIN88US=> MmjOV2FPT0WU
BEN NXPZcItCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G3R2lEPTB;ND61NlgyPSEQvF2= NF\RWmNUSU6JRWK=
BFTC-909 NG\lXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;rOGJHUUN3ME20MlU3Ojd3IN88US=> MXfTRW5ITVJ?
NCI-H2087 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDyTWM2OD12LkW4NVY1KM7:TR?= MnPRV2FPT0WU
RVH-421 M{jFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13YTWlEPTB;ND62OlY6KM7:TR?= MoTWV2FPT0WU
P30-OHK NWPxRYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITJ[HBKSzVyPUSuOlgxODhizszN MmLTV2FPT0WU
NCI-H28 M17tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX31SFdXUUN3ME20MlgyPjZzIN88US=> M2fjfXNCVkeHUh?=
ES6 NETxfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz4T2ZKSzVyPUSuPFMxOTZizszN M3Hlc3NCVkeHUh?=
769-P NYK3[IU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTRwOEW5NlYh|ryP MV;TRW5ITVJ?
OE33 NGD2fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDzWFFmUUN3ME20Mlg5OTZzIN88US=> Mn3VV2FPT0WU
SW982 NGT5UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpWHNKSzVyPUSuPVUxPjFizszN Mmm3V2FPT0WU
A388 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXRNZNKSzVyPUWuNFI6QDNizszN MX\TRW5ITVJ?
TI-73 MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTVwME[xPVQh|ryP NUnlVGxiW0GQR1XS
HCT-116 NITSTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK2TWM2OD13LkC5PFg6KM7:TR?= NUW3[plFW0GQR1XS
HuP-T3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH5TWM2OD13LkG4O|A6KM7:TR?= NHThUFNUSU6JRWK=
G-402 M{n0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwMUm0NVYh|ryP MV\TRW5ITVJ?
NCI-H1792 NULWU2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\qS4xKSzVyPUWuNlQ3OjJizszN MUTTRW5ITVJ?
NCI-H209 NVXiTok1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXic4VKSzVyPUWuNlU6PDJizszN NITUTVNUSU6JRWK=
NCI-H1650 NF\pRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;0WlhNUUN3ME21MlMxPjN2IN88US=> MY\TRW5ITVJ?
LCLC-97TM1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTVwM{G4NFgh|ryP NUmxT5UyW0GQR1XS
S-117 NG\JbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTVwM{[5O|Yh|ryP Mn7UV2FPT0WU
GI-ME-N NGnMfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTNS5YyUUN3ME21MlM6PjhzIN88US=> MmLyV2FPT0WU
NCI-H2122 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nRT2lEPTB;NT60PVM6PyEQvF2= M1\QN3NCVkeHUh?=
NCI-H1793 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDqUZdIUUN3ME21MlY4PTl|IN88US=> MXrTRW5ITVJ?
C2BBe1 Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLETWM2OD13LkewNFg5KM7:TR?= MY\TRW5ITVJ?
TE-12 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nUU2lEPTB;NT64NFU2PiEQvF2= NIPzd5ZUSU6JRWK=
LCLC-103H M1vCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj4TWM2OD13LkmxO{DPxE1? NF;xbXVUSU6JRWK=
A673 NYTRTmwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjnTWM2OD13LkmxPVMzKM7:TR?= NGXZSo5USU6JRWK=
BB30-HNC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPDVpoyUUN3ME21Mlk5OzZizszN MlXXV2FPT0WU
SF295 M3v3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPNTFBKSzVyPU[uNFA1OjJizszN M2HQVHNCVkeHUh?=
KU-19-19 M3Po[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTZwMEG3N|Eh|ryP MWjTRW5ITVJ?
CFPAC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvMTWM2OD14LkC0OFQ{KM7:TR?= NVPYeFRvW0GQR1XS
LoVo MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HLTmlEPTB;Nj6wOVA3OyEQvF2= MX7TRW5ITVJ?
8505C Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonVTWM2OD14LkC3OVc{KM7:TR?= MYHTRW5ITVJ?
GMS-10 NH\2e2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjaOJNKSzVyPU[uNVUxODJizszN NInMZ5NUSU6JRWK=
Ca9-22 NUfD[5J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjQbYVjUUN3ME22MlE3PzFizszN MmfEV2FPT0WU
DOK M{[1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTZwMkKwO|Ih|ryP MlPEV2FPT0WU
FADU MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK4cWZ4UUN3ME22MlI3ODN7IN88US=> NV;aXFliW0GQR1XS
BxPC-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fINWlEPTB;Nj6yO|MzKM7:TR?= NFjBNZlUSU6JRWK=
CAL-33 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLjWZFKSzVyPU[uNlkzODFizszN M4fCSHNCVkeHUh?=
SHP-77 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIexWY9KSzVyPU[uN|E2OTJizszN MoXjV2FPT0WU
LXF-289 NGLHTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3IWYZWUUN3ME22MlM{PDV3IN88US=> MmCyV2FPT0WU
GB-1 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZwM{iyJO69VQ>? NHrq[3VUSU6JRWK=
KS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPBO5o2UUN3ME22MlM5PDR5IN88US=> NU\GSGtrW0GQR1XS
D-502MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfRRXdKSzVyPU[uOFI{PzZizszN NHvINJVUSU6JRWK=
LAN-6 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\TVZNKSzVyPU[uOVExOjNizszN M{nVcnNCVkeHUh?=
H-EMC-SS M1vBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTZwNU[xOFch|ryP NIHiOXdUSU6JRWK=
LC-2-ad MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPSTWM2OD14Lk[wNFc3KM7:TR?= NYPrVoxbW0GQR1XS
NCI-H1693 NXr0PFF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHsTWM2OD14Lk[yNlE2KM7:TR?= M2e5PHNCVkeHUh?=
SK-N-FI M4S2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16zPWlEPTB;Nj63OVA1PCEQvF2= NVvjcHRXW0GQR1XS
D-423MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfjeJU5UUN3ME22Mlc3OTF5IN88US=> M{S4XHNCVkeHUh?=
KNS-42 M1TKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZwN{ixPVch|ryP Ml3EV2FPT0WU
GCT NFm5OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTZwOUO4JO69VQ>? MoLEV2FPT0WU
DSH1 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTlTWM2OD15LkC2N|Mh|ryP NHvVSnVUSU6JRWK=
D-247MG M3:2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPXTWM2OD15LkC3PFgyKM7:TR?= NF2wRWVUSU6JRWK=
NCI-SNU-5 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Yc2ZKSzVyPUeuNVg{PzFizszN M2PBSXNCVkeHUh?=
TE-6 NWO3bXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\mTWlEPTB;Nz6yNFYxOSEQvF2= NVzreGRoW0GQR1XS
NOMO-1 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTdwMkKxNlch|ryP MoXQV2FPT0WU
NB17 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki4TWM2OD15LkOwN|A6KM7:TR?= MXfTRW5ITVJ?
EW-22 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPnTWM2OD15LkO0N|Q5KM7:TR?= MV\TRW5ITVJ?
EW-13 M1fh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTdwM{WxOlIh|ryP NFPDZpZUSU6JRWK=
DOHH-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXpZ4piUUN3ME23MlQ1ODJizszN MnrSV2FPT0WU
TGBC1TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHDVpVKSzVyPUeuOFk5QTlizszN MnTYV2FPT0WU
GR-ST MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPWSG5CUUN3ME23MlUzPTl2IN88US=> MXTTRW5ITVJ?
KYSE-520 NH75cINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXiTWM2OD15LkW1OVE2KM7:TR?= NHjmSm9USU6JRWK=
CAPAN-1 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTdwNUm1NUDPxE1? MlTVV2FPT0WU
HCE-4 NHTWWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHqTmdKSzVyPUeuOlIzPzlizszN MVLTRW5ITVJ?
MLMA NV7xRVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn71TWM2OD15Lk[yPVU4KM7:TR?= M1e2N3NCVkeHUh?=
HT-144 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKxfJdKSzVyPUeuOlU{PjhizszN NH3CcJRUSU6JRWK=
KYSE-180 NXTWN3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTdwN{GxOlkh|ryP MnfRV2FPT0WU
TE-5 NEnZO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fyXGlEPTB;Nz65OVk4OSEQvF2= NYi4NIR4W0GQR1XS
IGROV-1 NXHaOJRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jPW2lEPTB;Nz65PFU2OSEQvF2= NHqzUGFUSU6JRWK=
NCI-H1581 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFriSYlKSzVyPUiuNFEzKM7:TR?= MnG1V2FPT0WU
SW1990 NG\rV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTqWIp1UUN3ME24MlA1PjV7IN88US=> MYHTRW5ITVJ?
EFM-19 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDGRWRSUUN3ME24MlA5PTR3IN88US=> NYjZfIZLW0GQR1XS
OGR-1 M4Htfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRThwNEOwNlMh|ryP Mn;qV2FPT0WU
U-118-MG NXnZbmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvCSpBKSzVyPUiuOFM1PjNizszN NIX3NmpUSU6JRWK=
SK-OV-3 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPqfVIzUUN3ME24MlQ3PzZ3IN88US=> MmD5V2FPT0WU
KNS-62 NHj6eXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n5b2lEPTB;OD61NVc3OSEQvF2= NF7WZZNUSU6JRWK=
GOTO MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDPfWdKSzVyPUiuOVc3OzVizszN M{DMdXNCVkeHUh?=
8305C MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvBTWM2OD16LkewOFg1KM7:TR?= MWfTRW5ITVJ?
RPMI-2650 M165V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLiTWM2OD16LkexPVU2KM7:TR?= MVPTRW5ITVJ?
NEC8 M13mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7kfHVKSzVyPUiuO|Q{ODdizszN M{DzZXNCVkeHUh?=
KYSE-450 M1rWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvhWmNKSzVyPUiuPFY2PDhizszN NFThOWFUSU6JRWK=
RMG-I NIDQRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLETWM2OD17LkG0NFU5KM7:TR?= MoW2V2FPT0WU
CAKI-1 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTlwM{G5O|kh|ryP NUjHOmF6W0GQR1XS
KYSE-510 NIG3R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxU2lEPTB;OT6zOVc4QCEQvF2= NVzs[VdmW0GQR1XS
A4-Fuk NIPyeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTlwM{[3NFEh|ryP MX;TRW5ITVJ?
AN3-CA MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4THXmlEPTB;OT60OVQ1PCEQvF2= M1roU3NCVkeHUh?=
SK-N-DZ NF;Zd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofGTWM2OD17LkeyPFQ6KM7:TR?= MnXNV2FPT0WU
HSC-2 M{[zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHkcWdKSzVyPUmuO|Y3OjlizszN Mnq4V2FPT0WU
EW-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTlwN{mzOlkh|ryP Ml\wV2FPT0WU
D-566MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTSemRWUUN3ME25Mlg{PjZ2IN88US=> NVjqOGp4W0GQR1XS
COLO-792 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTlwOUi3OFYh|ryP NUns[oFvW0GQR1XS
TE-10 NFvHWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTSOmp4UUN3ME2xNE4xOzl4IN88US=> M4jMeXNCVkeHUh?=
NCI-H650 NWXyUFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f6RmlEPTB;MUCuOFI5PiEQvF2= NFW3e2RUSU6JRWK=
U-266 NG[1XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j3OGlEPTB;MUCuOFU2KM7:TR?= Mlm5V2FPT0WU
Detroit562 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe2NmZKSzVyPUGxMlA2OTVizszN MVjTRW5ITVJ?
NH-12 M2n0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnJd3UxUUN3ME2xNU4yPDR4IN88US=> NEC4WnBUSU6JRWK=
CO-314 M1nHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrvRWdKSzVyPUGxMlI5PDJizszN MXfTRW5ITVJ?
IST-MEL1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnkTWM2OD1zMT61N|I{KM7:TR?= MXzTRW5ITVJ?
KNS-81-FD M2jhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDlRphEUUN3ME2xNU42PTJ5IN88US=> NYT3VZdXW0GQR1XS
SW1463 NXvKdodET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrkTWM2OD1zMT61PVg6KM7:TR?= M{LZbXNCVkeHUh?=
NCI-H23 NGO5epZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzpPXNEUUN3ME2xNU43PTV{IN88US=> NY[zSpF2W0GQR1XS
SK-MEL-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPEcJZKSzVyPUGxMlcyQTdizszN M4PwXXNCVkeHUh?=
NB13 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfBWmVwUUN3ME2xNk4yPDl3IN88US=> MnnZV2FPT0WU
Daoy MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF{LkK4OVYh|ryP MoPvV2FPT0WU
NCI-H1623 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\1[mlEPTB;MUKuN|gxOSEQvF2= NVTQNoJ[W0GQR1XS
NMC-G1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuwTWM2OD1zMj63NVch|ryP NX2weFd[W0GQR1XS
DK-MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLkTog2UUN3ME2xNk46PDh{IN88US=> M4fVRnNCVkeHUh?=
TCCSUP M2jxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni0TWM2OD1zMz6xNlg1KM7:TR?= Mn\6V2FPT0WU
SCC-15 NYDCRpA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\VeW9PUUN3ME2xN{4zPjVzIN88US=> MYfTRW5ITVJ?
NOS-1 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M176N2lEPTB;MUOuNlg6OyEQvF2= NFXpOlVUSU6JRWK=
RH-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\sNng6UUN3ME2xN{4{ODN5IN88US=> M3;udHNCVkeHUh?=
SK-MEL-3 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTvTWM2OD1zMz6zO|I5KM7:TR?= M3T3eHNCVkeHUh?=
NB5 M3PwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7iRXdjUUN3ME2xN{41ODZ5IN88US=> M2LPdXNCVkeHUh?=
SNU-387 NUC5c25LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrSVW1KSzVyPUGzMlUxPzJizszN M4ThUXNCVkeHUh?=
CAL-120 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0dVYyUUN3ME2xN{43PzF6IN88US=> NIPQe3pUSU6JRWK=
Mo-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF|LkewO{DPxE1? MnnxV2FPT0WU
LNCaP-Clone-FGC NFLW[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK5doRKSzVyPUGzMlc6QTJizszN NX;pW|ZxW0GQR1XS
CAN NIT5[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HzdGlEPTB;MUSuNFI5QCEQvF2= MVrTRW5ITVJ?
SK-MEL-30 NVrkR48yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm0TWM2OD1zND6wOlMh|ryP Mly5V2FPT0WU
COLO-678 NHLa[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G0dWlEPTB;MUSuNFgzOiEQvF2= MXzTRW5ITVJ?
SCC-9 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\rNWlKSzVyPUG0MlExOjFizszN M3OzW3NCVkeHUh?=
KINGS-1 NVz1W|dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1[YxvUUN3ME2xOE4yPDB{IN88US=> Ml;GV2FPT0WU
SL-513 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF2LkG4O{DPxE1? NWL6T45TW0GQR1XS
HLE MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLGOW9KSzVyPUG0MlM5PTJizszN M1f0OXNCVkeHUh?=
SW1573 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTqVpZXUUN3ME2xOE41PDN3IN88US=> NGTlSJBUSU6JRWK=
KYSE-140 NHLFfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yzemlEPTB;MUSuOlMzPyEQvF2= NFfhdIFUSU6JRWK=
SK-PN-DW Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\iNI9mUUN3ME2xOE45ODBzIN88US=> NUP4cnFDW0GQR1XS
A253 NHLL[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TufmlEPTB;MUWuNFYzPSEQvF2= MY\TRW5ITVJ?
CAL-12T M{XFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WxT2lEPTB;MUWuOFY3OiEQvF2= Mke1V2FPT0WU
COLO-679 M3HHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;nRXVKSzVyPUG1Mlc3QDNizszN MX;TRW5ITVJ?
UACC-257 NF3zU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf0bY4xUUN3ME2xOk4yOjBzIN88US=> Mli3V2FPT0WU
U-87-MG NUnPSVlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjXUZpKSzVyPUG2MlM2OjNizszN NFG4WFFUSU6JRWK=
HCC1806 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF4LkewO|Eh|ryP MoDVV2FPT0WU
NCI-H2170 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF5LkK0OFgh|ryP NVnQd|lDW0GQR1XS
AGS MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfuXFZKSzVyPUG3MlM5ODhizszN MoPNV2FPT0WU
MEL-HO MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPoTWM2OD1zNz63OVA{KM7:TR?= M3y2b3NCVkeHUh?=
SW48 NGfUV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF5Lke3NVYh|ryP MkOxV2FPT0WU
HuP-T4 NFS4W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTHTWM2OD1zOD6wNlA3KM7:TR?= M4DBN3NCVkeHUh?=
NCI-H720 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknQTWM2OD1zOD6xOFAzKM7:TR?= MmPWV2FPT0WU
RCC10RGB NXrwUZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLTTWM2OD1zOD6xOlk4KM7:TR?= NW[5cm9PW0GQR1XS
HD-MY-Z MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF6LkKyOVQh|ryP M4W2NXNCVkeHUh?=
A427 M3jUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;sTWlEPTB;MUiuOVA6PCEQvF2= NGXJXoJUSU6JRWK=
HCC2998 NGP1c|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nPUWlEPTB;MUiuOlA2OSEQvF2= MmOzV2FPT0WU
EPLC-272H NVL2cWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLtW3pKSzVyPUG5MlA1OzRizszN NX3XcohjW0GQR1XS
C32 M1y1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXhTWM2OD1zOT6wOFUh|ryP Mm\xV2FPT0WU
UMC-11 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknnTWM2OD1zOT6yNVI{KM7:TR?= NIDnVHVUSU6JRWK=
CaR-1 M3[ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXrTWM2OD1zOT62PFA1KM7:TR?= NH20NnNUSU6JRWK=
KYSE-410 NH3vXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXoTWM2OD1zOT65NVM6KM7:TR?= M4H5XnNCVkeHUh?=
HuCCT1 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;OTWM2OD1{MD62Nlk1KM7:TR?= M2nvdnNCVkeHUh?=
LB996-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[3PGxKSzVyPUKwMlcyPjhizszN MYnTRW5ITVJ?
KYSE-70 NH7PZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXLTWM2OD1{MD64NFU6KM7:TR?= NWDMO2xOW0GQR1XS
CAL-72 NYXaVHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnpTWM2OD1{MD65NVUh|ryP NH;QR3JUSU6JRWK=
Capan-2 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\vTWM2OD1{MT6wOFE{KM7:TR?= NYrzU5R4W0GQR1XS
PANC-08-13 M4rQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nUXGlEPTB;MkGuNlUyPSEQvF2= MWPTRW5ITVJ?
SBC-1 NUjG[VZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT6[nlKSzVyPUKxMlMxQDFizszN MoHnV2FPT0WU
MFM-223 NV;VUZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJzLkOzOFIh|ryP NUXXUXU6W0GQR1XS
BB49-HNC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJzLkW3NVYh|ryP MWHTRW5ITVJ?
SH-4 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfKXXFoUUN3ME2yNU43PjF6IN88US=> NF\Q[lBUSU6JRWK=
HuO9 M{\WWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3OTWM2OD1{MT65PFI2KM7:TR?= MYXTRW5ITVJ?
AM-38 NWXEcJVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ{LkC0PFUh|ryP Mn30V2FPT0WU
A431 NX3k[YFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nRXGlEPTB;MkOuNlEyQSEQvF2= M1zL[XNCVkeHUh?=
YAPC NH\lV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTpU4lwUUN3ME2yN{4zPjVzIN88US=> MlnYV2FPT0WU
LU-139 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ|LkS4NFkh|ryP NXzEcVdjW0GQR1XS
HEC-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ|LkS5N|ch|ryP NV3YcZhIW0GQR1XS
SCC-25 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm3TWM2OD1{ND6zNFA3KM7:TR?= MXvTRW5ITVJ?
HT-29 NG\1[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX1TWM2OD1{ND6zPFI{KM7:TR?= NH;qN5hUSU6JRWK=
PC-14 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf0SmRKSzVyPUK0MlY2PzFizszN NITqfXJUSU6JRWK=
Calu-6 M3jhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KwPWlEPTB;MkWuOVA4OSEQvF2= M2HMUnNCVkeHUh?=
SJRH30 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXGN5BCUUN3ME2yOU43PDl4IN88US=> MkXUV2FPT0WU
ChaGo-K-1 M2[ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\YSo5KSzVyPUK2MlE3OjlizszN NYLqS5lVW0GQR1XS
IA-LM M364Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;sZ2FKSzVyPUK2MlM3PDVizszN MWPTRW5ITVJ?
GP5d MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ4LkS0PVEh|ryP NVTH[2RwW0GQR1XS
NCI-H2291 NIHKV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\h[GlEPTB;Mk[uOlU1OSEQvF2= MXTTRW5ITVJ?
BALL-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqxTWM2OD1{Nj65N|k4KM7:TR?= MoH3V2FPT0WU
HCC1954 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNRmlEPTB;Mk[uPVgxQCEQvF2= MWnTRW5ITVJ?
NCI-H2452 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrZNGxKSzVyPUK3MlQyPjNizszN NVrxUWZqW0GQR1XS
LU-99A M{fHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ5LkW1PFIh|ryP NXPNeG5MW0GQR1XS
NTERA-S-cl-D1 M1vtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7ITWM2OD1{Nz63Nlk6KM7:TR?= MXnTRW5ITVJ?
PANC-10-05 M2G5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T4R2lEPTB;MkeuO|c4PSEQvF2= NFjIZnpUSU6JRWK=
NCI-H2405 NVrRZ5pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLkdplKSzVyPUK3Mlk{QDdizszN NWfKRpkxW0GQR1XS
MDA-MB-415 NXSyVXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknYTWM2OD1{OD60NVM4KM7:TR?= MUPTRW5ITVJ?
NCI-H2342 NGrP[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnyTWM2OD1{OD61NlgyKM7:TR?= MUjTRW5ITVJ?
TGBC24TKB NFuzNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LHVWlEPTB;MkiuO|EyPyEQvF2= MmTiV2FPT0WU
LU-134-A MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj6TWM2OD1{OD65NlYyKM7:TR?= NFGzcYVUSU6JRWK=
SCC-4 MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fvWGlEPTB;M{GuNFQ6PCEQvF2= MVPTRW5ITVJ?
Saos-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fpWWlEPTB;M{GuPVMxPiEQvF2= M2fTWnNCVkeHUh?=
RERF-LC-MS MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfVTWM2OD1|Mj64NlMyKM7:TR?= M1fsRXNCVkeHUh?=
M14 NFjSSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTDTWM2OD1|Mj65O|Y1KM7:TR?= Moi1V2FPT0WU
HPAF-II NF3HNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu2TWM2OD1|Mz61NFEyKM7:TR?= NHTEd2JUSU6JRWK=
NCI-H1755 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfmdVRKSzVyPUO0MlM{ODVizszN NYjjT5JnW0GQR1XS
D-392MG NH\pbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\nflc4UUN3ME2zOU45Pjd2IN88US=> NX;OTY84W0GQR1XS
A704 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXGUZlmUUN3ME2zOk4xPDJ5IN88US=> NV\DfGdIW0GQR1XS
CP50-MEL-B NX3OUVF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXqbYFKSzVyPUO2MlE6OTFizszN NWLzVHFCW0GQR1XS
EW-18 NV21PHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny0TWM2OD1|Nj60OVIh|ryP MUTTRW5ITVJ?
WM-115 M3zVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPZTWM2OD1|Nj64NFk6KM7:TR?= NIHnNJdUSU6JRWK=
LU-65 NWTiUJppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYftfFhpUUN3ME2zO{4yPDF5IN88US=> Mn;mV2FPT0WU
NCI-H1563 NWjIU2NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrnVYN4UUN3ME2zO{4zPDh2IN88US=> MmDNV2FPT0WU
DBTRG-05MG MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e0N2lEPTB;M{iuNFY6OSEQvF2= M1PyfHNCVkeHUh?=
NCI-H630 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7UTWM2OD1|OD60O|E1KM7:TR?= NETuV5RUSU6JRWK=
NCI-H1155 NXX2epVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13qWWlEPTB;M{muNlQzKM7:TR?= MkS3V2FPT0WU
OVACR-3 M2jRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z0R2lEPTB;M{muPVE6PSEQvF2= NVG0NGVrW0GQR1XS
OAW-42 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T6N2lEPTB;NECuOFI2QCEQvF2= MkP2V2FPT0WU
JVM-2 NVfCZ3lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmWwTWM2OD12MT6yOFE2KM7:TR?= MVXTRW5ITVJ?
C3A NEe5RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CwcWlEPTB;NEGuN|Q1PyEQvF2= NF7qb3FUSU6JRWK=
HT55 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;xTWM2OD12Mj6yPFQyKM7:TR?= M{j3WHNCVkeHUh?=
OVCAR-4 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e4OmlEPTB;NEKuNlk4PCEQvF2= M3\PXnNCVkeHUh?=
MEG-01 NELVfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fac2lEPTB;NEKuOFYyPiEQvF2= M3nGUnNCVkeHUh?=
NCI-H82 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR|Lkm4PVIh|ryP MVrTRW5ITVJ?
JEG-3 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTR2Lkm0O{DPxE1? NITkTZhUSU6JRWK=
BPH-1 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXaOpFOUUN3ME20Ok4{QTl6IN88US=> MXfTRW5ITVJ?
MPP-89 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13VWGlEPTB;NEeuNlg6QCEQvF2= M4\uNHNCVkeHUh?=
ALL-PO MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P4XGlEPTB;NEeuOFE5QCEQvF2= M1P5cHNCVkeHUh?=
HT NVvHeHZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u2R2lEPTB;NEeuOFkzKM7:TR?= MV\TRW5ITVJ?
NCI-H2347 M1T2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\wNYZKSzVyPUS4MlA4OTVizszN M2rJWXNCVkeHUh?=
A2780 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITuUohKSzVyPUS5MlQzOjhizszN NUDHZlFbW0GQR1XS
KARPAS-299 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zCPWlEPTB;NEmuOVEyQSEQvF2= MUXTRW5ITVJ?
NCI-H1651 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITUfIRKSzVyPUS5Mlg5OjFizszN M2nrdHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; 

PubMed: 30300583     


Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells.

pRb(S807, 811) / CDK4 / CDK6 / PARP; 

PubMed: 28453226     


Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. 

LC3-I / LC3-II; 

PubMed: 28453226     


Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. 

pAMPKα(T172) / pULK1(S317); 

PubMed: 28453226     


Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. 

SMAD2 (pS255); 

PubMed: 30343527     


T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.

30300583 28453226 30343527
Growth inhibition assay
Cell viability; 

PubMed: 29670090     


Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.

29670090
Immunofluorescence
SAHF/ATRX; 

PubMed: 26988987     


DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. 

LC3B; 

PubMed: 28453226     


LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).

26988987 28453226
ELISA
PGE2; 

PubMed: 26540629     


The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.

26540629
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

- Collapse

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

- Collapse
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A
Smiles Cl.CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2N(C5CCCC5)C1=O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03870919 Not yet recruiting Drug: Palbociclib|Other: locoregional treatment Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer October 15 2019 Not Applicable
NCT03900884 Not yet recruiting Drug: Venetoclax|Drug: Palbociclib|Drug: Letrozole Breast Neoplasm Female Peter MacCallum Cancer Centre Australia September 2019 Phase 1
NCT03844997 Recruiting Drug: Palcociclib|Drug: CPX-351 Acute Myeloid Leukemia|AML Aziz Nazha|Case Comprehensive Cancer Center May 31 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID